ORIC Pharmaceuticals announced acceptance of multiple abstracts for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. The abstracts, dated March 17, 2026, will be presented on April 22, 2026, during the conference’s poster session.
The abstracts highlight preclinical and early clinical activity of ORIC‑944, the company’s orally bioavailable allosteric inhibitor of the PRC2 complex that targets the EED subunit. The data demonstrate the compound’s potency and selectivity, and suggest it can overcome resistance mechanisms in metastatic castration‑resistant prostate cancer when combined with androgen‑receptor inhibitors.
Acceptance of the abstracts provides ORIC with a platform to share its findings with the oncology research community ahead of the planned initiation of a Phase 3 trial in mCRPC in the first half of 2026. The company’s Phase 1b study of ORIC‑944 in combination with AR inhibitors has already shown promising PSA responses and circulating tumor DNA reductions.
ORIC’s pipeline also includes enozertinib for non‑small cell lung cancer, and the company raised $244 million in 2025, giving it a cash runway through the second half of 2028. The abstract acceptance marks a key milestone in ORIC’s development strategy and signals continued progress toward regulatory approval.
The acceptance of the abstracts at AACR is a significant event for a clinical‑stage biopharmaceutical company, as it allows ORIC to generate early scientific interest and gauge community feedback on its lead candidate before the Phase 3 trial launch.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.